Skip to main content
Caplight Logo









Nouscom

Nouscom

Private
BaselHealthcare & Life Scienceshttps://nouscom.com/

Last Round

Series C

Mar 21, 2024

Total Funding Raised

$226.6M

Company Overview

Nouscom is a biotechnology company that develops engineered viral vector vaccines for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cancer vaccineimmuno-oncologyviral vector platformpersonalized cancer vaccineneoantigencancer immunotherapyLynch syndromebioinformaticsclinical stage biotechoff-the-shelf vaccinecancer vaccine startupdrug discoveryprecision medicinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nouscom Comparables

Compare Nouscom with similar companies based on industry and business-model similarity.

Nouscom comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Transgene SA
80%
Gritstone bio
78%
Nykode Therapeutics
78%

Nouscom Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 21, 2024
Series CNov 14, 2023
Series BNov 6, 2017
Series AMay 17, 2016

Key People

Founding team and executive leadership

Marina Udier Blagovic

Chief Executive Officer

Executive Team

Tiffany Muller

Chief Financial Officer

Executive Team

Nouscom Investors

Notable investors and investment history

Nouscom investors
InvestorRounds
EQT Life SciencesSeries C, Series B, Series A
XGEN VentureSeries C
Andera PartnersSeries C
M VenturesSeries C
Indaco Venture Partners SGRSeries C
5AM VenturesSeries B, Series C
Versant VenturesSeries B, Series C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 21, 2024

    $82M round led by Andera Partners and M Ventures.

  • Nov 14, 2023

    $82M round raised

Nouscom Filings

Explore SEC and related filing metadata, where available.

Nouscom filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nouscom's valuation, stock price, and market status.

Is Nouscom a public or private company?

Nouscom is a private company.

What is the current stock price of Nouscom?

Nouscom is a private company with no public stock price. No recent secondary market data is available.

How much is Nouscom worth (valuation)?

Valuation information for Nouscom is not publicly available.

Can I buy Nouscom stock?

Nouscom shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nouscom's last funding round?

Nouscom's most recent funding round was Series C on March 21, 2024.

Who are the main investors in Nouscom?

Key investors in Nouscom include Andera Partners, M Ventures, Bpifrance, Versant Ventures, Abingworth.

Will Nouscom IPO soon?

No public IPO plans have been announced for Nouscom.

How can I track Nouscom secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nouscom's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range45
Year Founded2015
Last FundingMar 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?